Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 13/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20588060 | 1.00 | S1PR1 (0.49) | S1PR1S1PR3BRD4PSMB8PRKCQ | |
| SCHEMBL23523996 | 0.87 | S1PR1 (0.48) | S1PR1S1PR3PRKCQCDK1KDR | |
| SCHEMBL30355473 | 0.87 | S1PR1 (0.48) | S1PR1S1PR3PRKCQCDK1KDR | |
| SCHEMBL30355611 | 0.86 | PSMD11 (0.42) | S1PR1S1PR3 | |
| SCHEMBL23524372 | 0.86 | PSMD11 (0.42) | S1PR1S1PR3 | |
| SCHEMBL23523944 | 0.84 | S1PR1 (0.36) | S1PR1S1PR3L3MBTL1 | |
| SCHEMBL30355759 | 0.84 | S1PR1 (0.36) | S1PR1S1PR3L3MBTL1 | |
| SCHEMBL23524010 | 0.83 | S1PR1 (0.39) | S1PR1S1PR3L3MBTL1 | |
| SCHEMBL30355717 | 0.83 | S1PR1 (0.39) | S1PR1S1PR3L3MBTL1 | |
| SCHEMBL23524416 | 0.82 | CDC7 (0.41) | S1PR1S1PR3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114585360-B | Methods of using the same for treating epilepsy | 特维娜有限公司 | 2025-04-29 | — | — | CN | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | TREVENA, INC. | 2023-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885BRD4 808/4885 |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885BRD4 1755/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885BRD4 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.